These drugs are part of an emerging class of nutrient-stimulated hormone-based therapeutics, acting as incretin mimetics to target G-proteincoupled receptors like GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon
Insurance coverage for such drugs is currently typically approved when patients have other conditions that are often tied to obesity, such as diabetes, heart disease and cancer
Anti-Inflammatory and Anti-Fibrotic Effects Chronic low-grade perifollicular inflammation the kind that slowly scars follicle tissue without causing obvious redness or symptoms is increasingly recognized as a driver of hair miniaturization
Consultation with an endocrinologist is recommended in patients who develop elevated calcitonin concentrations or have thyroid nodules detected during imaging studies or physical exam
In addition, increased release of multiple GI hormones including vasoactive agents (e.g
InjectCos compounded semaglutide program includes comprehensive medical support, making it both affordable and safe